The worldwide medical impact of hepatitis D virus infection: Focus to Central Asia
Yükleniyor...
Dosyalar
Tarih
2025
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Academic Press
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Hepatitis D virus (HDV) requires hepatitis B virus (HBV) for its replication. Concurrent infection with HBV and HDV results in more severe disease outcomes than infection with HBV alone, inducing cirrhosis, fulminant hepatitis, and hepatocellular carcinoma, and representing a significant cause of global mortality. Central Asia remains an area of high HDV prevalence but local features of the infection were poorly detailed in the past. Until recently, interferon has represented the only treatment option in patients with chronic hepatitis D; however, it is associated with low efficacy and a high burden of side effects. The discovery of the entry inhibitor bulevirtide has represented a breakthrough in HDV treatment. Other compounds (i.e., lonafarnib, new anti-hepatitis B virus drugs) are under development to provide alternative or combined strategies for HDV cure.
Açıklama
Anahtar Kelimeler
Central Asia, Hepatitis D Virus (HDV), Hepatitis B Virus (HBV)
Kaynak
Hepatology: An Evidence-Based Clinical Compendium
WoS Q DeÄŸeri
Scopus Q DeÄŸeri
Cilt
Sayı
Künye
Aghayeva, G., Rizzetto, M., Örmeci, N., Turcanu, A., Abbas, Z., & Bedewy, E. (2025). The worldwide medical impact of hepatitis D virus infection: Focus to Central Asia. S. K. Satapathy, M. Al-Mahtab, S. P. Singh, S. M. F. Akbar, A. Ala, T. D. Schiano, (Eds). Hepatology: An Evidence-Based Clinical Compendium, (pp. 655-673). London: Academic Press.
